Verenium (NASDAQ: VRNM) is one of 32 publicly-traded companies in the “Commodity Chemicals” industry, but how does it weigh in compared to its competitors? We will compare Verenium to similar companies based on the strength of its valuation, earnings, risk, profitability, dividends, analyst recommendations and institutional ownership.

Volatility and Risk

Verenium has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Verenium’s competitors have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.

Profitability

This table compares Verenium and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Verenium N/A N/A N/A
Verenium Competitors -29.50% 24.34% 5.63%

Valuation & Earnings

This table compares Verenium and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Verenium N/A N/A -2.56
Verenium Competitors $4.01 billion $340.26 million 134.02

Verenium’s competitors have higher revenue and earnings than Verenium. Verenium is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

70.9% of shares of all “Commodity Chemicals” companies are held by institutional investors. 7.8% of shares of all “Commodity Chemicals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Verenium and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verenium 0 0 0 0 N/A
Verenium Competitors 106 826 1223 36 2.54

As a group, “Commodity Chemicals” companies have a potential downside of 0.48%. Given Verenium’s competitors higher probable upside, analysts plainly believe Verenium has less favorable growth aspects than its competitors.

Summary

Verenium competitors beat Verenium on 7 of the 8 factors compared.

About Verenium

Verenium Corporation (Verenium) is an industrial biotechnology company. The Company develops and commercializes enzymes for use in a range of industrial processes. It manufactures and markets its enzyme products in the fields of animal health and nutrition, grain processing, oilfield services and other industrial processes, such as pulp and paper and textiles. As of December 31, 2012, it marketed commercial enzyme products, either independently or in collaboration with its partners. In addition, it has developed a pipeline of enzyme product candidates. Its products are organized into four product lines: animal health and nutrition, grain processing, oilfield services and other industrial processes. As of December 31, 2012, it markets nine commercial enzyme products. In October 2013, BASF SE acquired 71% stake in the Company.

Receive News & Ratings for Verenium Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verenium Corp and related companies with MarketBeat.com's FREE daily email newsletter.